Chugai and Novartis Pharma to Terminate Co-Marketing Agreement of Aromatase Inhibitor “Femara® Tablets 2.5 mg,” a Treatment for Breast Cancer after Menopause Mittwoch, 06. Januar 2016 - 06:10
TOKYO, January 6, 2016 - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519)
announced today that Chugai and Novartis Pharma K.K. have agreed to
terminate the agreement regarding co-marketing of aromatase inhibitor
“Femara® tablets 2.5 mg” (generic name: letrozole, hereafter Femara®), a treatment for breast cancer after menopause in Japan, as of January 31, 2016.
Novartis Pharma will be solely responsible for the distribution and commercialization of Femara® in Japan from February 1, 2016.
Chugai and Novartis Pharma will cooperate to accomplish a smooth transition. During the transition period, both companies will maintain the same level of product supply and adequate commercial activities to satisfy any medical needs.
About Femara® Tablets 2.5 mg
| Generic Name: | Letrozole |
|---|---|
| Brand Name: | Femara® Tablets 2.5 mg |
| Approval Date: | January 23, 2006 |
| Launch Date: | May 11, 2006 |
| Indication: | Breast cancer after menopause |
| Dosage and administration: | The usual adult dosage is 2.5 mg administered orally once daily. |
| Drug Price: | JPY 674.1/Tablet |
| Manufacturer & Distributor: | Novartis Pharma K.K. |
| Distribution and commercialization: | Novartis Pharma K.K. (on or after February 1, 2016) |
Contact:
For Media
Chugai Pharmaceutical Co., Ltd
Media Relations Group, Corporate Communications Dept.,
Koki Harada
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
For Investors
Chugai Pharmaceutical Co., Ltd
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp
[
PDF 147KB]